Mirapexin

How to order Mirapexin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Mirapexin on Prescriptsy

Mirapexin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Mirapexin is the brand name for pramipexole, a non-ergot dopamine agonist licensed in the United Kingdom for two distinct neurological conditions: Parkinson's disease and moderate to severe restless legs syndrome (RLS).

In Parkinson's disease, Mirapexin can be used as initial monotherapy in early disease or as adjunctive therapy alongside levodopa in more advanced stages.

For restless legs syndrome, low-dose pramipexole effectively reduces the distressing sensorimotor symptoms that disrupt sleep and quality of life.

Parkinson's disease affects approximately 153,000 people in the UK, with around 18,000 new diagnoses each year.

Restless legs syndrome is even more common, affecting an estimated 5 to 10% of the adult population, though many cases remain undiagnosed.

This page provides a comprehensive clinical overview of Mirapexin, including how it works, dosing guidance, side effects, important safety warnings (particularly regarding impulse control disorders and sudden onset of sleep), and how to obtain a prescription in the UK.

Important safety information about Mirapexin

Before reading further, note the following key safety points about Mirapexin.

• Mirapexin may cause impulse control disorders including pathological gambling, compulsive spending, binge eating, and hypersexuality. Patients and carers must be aware of these risks and report any behavioural changes promptly.
• Sudden onset of sleep may occur during daily activities, including driving, without prior drowsiness. Patients experiencing sleep episodes must not drive or operate machinery.
• Do not stop Mirapexin suddenly. Abrupt withdrawal may cause a serious condition resembling neuroleptic malignant syndrome.
• Dose adjustments are required for patients with impaired kidney function.

What is Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra pars compacta, a region of the midbrain involved in the control of movement.

Dopamine is a neurotransmitter essential for coordinating smooth, purposeful movement.

As dopamine levels fall, the balance between excitatory and inhibitory pathways within the basal ganglia is disrupted, resulting in the cardinal motor symptoms of Parkinson's disease: bradykinesia (slowness of movement), rigidity (muscle stiffness), resting tremor (shaking, typically starting in one hand), and postural instability (impaired balance).

Non-motor symptoms are increasingly recognised as a major component of Parkinson's disease and include depression, anxiety, cognitive impairment, sleep disturbance, constipation, urinary dysfunction, pain, fatigue, and anosmia (reduced sense of smell).

These symptoms can be as disabling as the motor features and may precede the motor diagnosis by years.

Parkinson's disease in the UK

Parkinson's UK estimates that approximately 153,000 people in the UK are living with Parkinson's disease, making it the second most common neurodegenerative condition after Alzheimer's disease.

The average age of onset is around 60, but early-onset Parkinson's can affect people in their 30s and 40s.

NICE Guideline NG71 (Parkinson's disease in adults) provides comprehensive recommendations on diagnosis, pharmacological and non-pharmacological management, and palliative care.

What is restless legs syndrome

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor neurological disorder characterised by an irresistible urge to move the legs, usually accompanied by uncomfortable sensations such as crawling, tingling, burning, or aching deep within the limbs.

Symptoms characteristically worsen during periods of rest or inactivity, are most severe in the evening and at night, and are temporarily relieved by movement.

RLS significantly disrupts sleep onset and maintenance, leading to chronic sleep deprivation, daytime fatigue, impaired concentration, and reduced quality of life.

The pathophysiology of RLS involves dysfunction of the dopaminergic A11 diencephalospinal pathway and, in many cases, brain iron deficiency.

Low-dose dopamine agonists such as pramipexole are effective first-line pharmacological treatment for moderate to severe RLS, as recommended by NICE Clinical Knowledge Summaries and European RLS guidelines.

How Mirapexin works: mechanism of action

Pramipexole is a non-ergot dopamine agonist that acts by directly stimulating dopamine receptors in the brain.

It has high affinity for the D2 subfamily of dopamine receptors (D2, D3, and D4), with preferential binding to the D3 subtype.

The D3 receptor is concentrated in the mesolimbic system, a brain region involved in motivation, reward, and emotional processing.

This selectivity may explain the observed benefits of pramipexole on mood and certain non-motor symptoms in Parkinson's disease, though the same mechanism may also underlie the risk of impulse control disorders.

In Parkinson's disease, pramipexole compensates for the reduced dopaminergic transmission resulting from nigrostriatal neuronal loss.

By directly activating post-synaptic dopamine receptors, it does not depend on the residual capacity of surviving neurons to synthesise and release dopamine (as levodopa does).

This makes dopamine agonists useful in early Parkinson's disease, where they can delay the need for levodopa and the associated risk of motor complications (wearing-off, on-off fluctuations, and dyskinesia).

In restless legs syndrome, the therapeutic effect is mediated through dopaminergic modulation of the A11 diencephalospinal pathway.

The low doses used for RLS (typically 0.088 to 0.54 mg daily) produce symptomatic relief with a lower side effect burden than the higher doses needed for Parkinson's disease.

However, long-term use may lead to augmentation, a paradoxical worsening of symptoms that requires treatment modification.

Unlike older ergot-derived dopamine agonists (such as cabergoline and bromocriptine), pramipexole does not carry a risk of cardiac valvular fibrosis, retroperitoneal fibrosis, or pulmonary fibrosis.

This represents an important safety advantage. NICE NG71 recommends non-ergot dopamine agonists as the preferred class when a dopamine agonist is indicated.

Clinical evidence and national guidelines

The efficacy of pramipexole in Parkinson's disease has been established in several large randomised controlled trials.

The CALM-PD study compared initial treatment with pramipexole versus levodopa in early Parkinson's disease and found that initial pramipexole therapy was associated with a significantly lower incidence of dyskinesia (24.5% versus 54%) and wearing-off (47% versus 62.7%) over a 4-year follow-up, though levodopa provided slightly better symptomatic control of motor symptoms.

In advanced Parkinson's disease, the addition of pramipexole to levodopa reduced off-time and allowed levodopa dose reductions.

NICE NG71 recommends dopamine agonists, levodopa, or MAO-B inhibitors as initial pharmacological treatment options in early Parkinson's disease, with the choice guided by the patient's symptoms, circumstances, and preferences.

Dopamine agonists are preferred in younger patients (under 40) to delay the onset of motor complications, while levodopa may be chosen first in older patients or those prioritising the best possible motor control.

For restless legs syndrome, a Cochrane review confirmed that pramipexole significantly reduces symptom severity compared with placebo, with improvement on the International RLS Severity Scale.

NICE CKS recommends low-dose dopamine agonists (pramipexole or ropinirole) as first-line pharmacological treatment for moderate to severe RLS when non-pharmacological measures have been insufficient.

Dosage and administration

Mirapexin is available as immediate-release tablets (taken three times daily) and prolonged-release tablets (taken once daily).

The dose depends on the indication, the formulation, and the patient's renal function.

Doses are expressed as pramipexole base (some references use pramipexole salt equivalents, which are higher; prescribers should check which convention is being used).

Parkinson's disease: titration schedule

For immediate-release Mirapexin, the recommended titration schedule starts at 0.088 mg three times daily during week 1, increasing to 0.18 mg three times daily in week 2, 0.35 mg three times daily in week 3, and then increasing further if needed in weekly steps of 0.18 mg per dose, up to a maximum of 1.1 mg three times daily (3.3 mg per day).

The prolonged-release formulation follows a similar total daily dose range, taken once daily: starting at 0.26 mg daily and increasing at weekly intervals to a maximum of 3.15 mg daily.

Restless legs syndrome

For RLS, only the immediate-release formulation is licensed. The starting dose is 0.088 mg once daily, taken 2 to 3 hours before bedtime.

If needed, the dose can be increased at intervals of 4 to 7 days to 0.18 mg daily, and then to a maximum of 0.54 mg daily.

Renal impairment

Pramipexole is primarily excreted unchanged by the kidneys.

In patients with moderate renal impairment (creatinine clearance 20 to 50 mL/min), the starting dose and maximum dose should be reduced.

In severe renal impairment (creatinine clearance below 20 mL/min), further dose reductions are necessary. Your prescriber or specialist will calculate the appropriate dose based on kidney function.

Side effects of Mirapexin

Common side effects

Nausea is the most frequently reported side effect, particularly during the initial titration phase. Taking tablets with food may help.

Dizziness, somnolence (excessive daytime sleepiness), and insomnia are also common. Headache, constipation, and fatigue occur in a significant proportion of patients.

Peripheral oedema (swelling of the ankles and legs) and weight gain have been reported.

Impulse control disorders

Impulse control disorders (ICDs) are a clinically important side effect of all dopamine agonists, including pramipexole. These include pathological gambling, binge eating disorder, compulsive buying, and hypersexuality.

ICDs may affect up to 17% of patients on dopamine agonists, according to the DOMINION study. The MHRA has issued specific safety advice about these risks.

Patients often do not recognise the behaviours as drug-related, which is why carers and family members play a vital role in monitoring.

If ICDs develop, dose reduction or discontinuation of the dopamine agonist is usually necessary. Some patients continue to experience ICDs even after dose reduction, requiring complete withdrawal.

Sudden onset of sleep

Pramipexole can cause sudden onset of sleep during daily activities such as eating, talking, or driving. These episodes may occur without preceding drowsiness.

The risk increases with higher doses and with concomitant sedating medications.

Patients must be informed of this risk before starting treatment and must not drive or operate dangerous machinery if they experience excessive sleepiness or sudden sleep episodes.

Other notable side effects

Hallucinations (typically visual) may occur, particularly in elderly patients and those taking high doses or concurrent levodopa.

Postural hypotension (a drop in blood pressure on standing) may cause dizziness, lightheadedness, or fainting, especially during initial titration.

Dyskinesia may develop or worsen when pramipexole is used alongside levodopa, usually requiring levodopa dose adjustment rather than pramipexole discontinuation.

When to seek medical advice

Contact your GP, Parkinson's nurse, or NHS 111 if you experience excessive sleepiness, episodes of falling asleep unexpectedly, unusual urges or behavioural changes, persistent nausea, confusion, hallucinations, or swollen ankles.

Seek emergency care by calling 999 if you experience sudden collapse, severe rigidity, or high fever after stopping or missing doses, as this may indicate neuroleptic malignant-like syndrome.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Impulse control disorders

The MHRA advises that all patients starting a dopamine agonist should be warned about the risk of impulse control disorders and that this warning should be documented in the clinical notes.

Patients and their carers should be advised to report any new or worsening behavioural symptoms promptly. Regular screening for ICDs should be part of routine clinical review.

If pathological gambling, compulsive spending, hypersexuality, or binge eating develops, the dopamine agonist dose should be reduced or the drug discontinued.

Driving and sudden onset of sleep

Patients must be informed that pramipexole may affect their ability to drive and operate machinery.

The DVLA must be notified if excessive daytime sleepiness or sudden sleep episodes occur.

Patients who have experienced sudden onset of sleep must not drive until the episodes have resolved and medical assessment confirms that driving is safe.

Discontinuation

Mirapexin should not be stopped abruptly. Gradual dose reduction over at least one week is recommended.

Abrupt withdrawal may precipitate neuroleptic malignant-like syndrome (fever, muscle rigidity, altered consciousness) or severe dopamine agonist withdrawal syndrome (DAWS), characterised by apathy, depression, anxiety, fatigue, sweating, and generalised pain.

If DAWS develops, temporary re-escalation of the dopamine agonist dose, with a subsequent slower taper, may be necessary.

Pregnancy and breastfeeding

There are limited human data on the use of pramipexole during pregnancy. Animal studies have shown reproductive toxicity at high doses.

Mirapexin should only be used during pregnancy if the potential benefit to the mother justifies the risk to the foetus.

As pramipexole may suppress prolactin, it could inhibit lactation. Breastfeeding is not recommended during treatment.

How to get a Mirapexin prescription in the UK

Mirapexin is classified as a prescription-only medicine (POM) in the UK. It is typically initiated by a neurologist or specialist with expertise in Parkinson's disease or movement disorders.

For restless legs syndrome, treatment may be initiated in primary care following assessment and exclusion of secondary causes (including iron deficiency).

Ongoing prescriptions may be managed by your GP as part of a shared-care arrangement with the specialist team.

The standard NHS prescription charge in England is currently 9.90 pounds per item. Prescriptions are free in Scotland, Wales, and Northern Ireland. Patients with certain long-term conditions may be entitled to free prescriptions in England via a medical exemption certificate.

Living with Parkinson's disease: practical support

Parkinson's disease is a long-term condition that requires ongoing medical management, regular specialist review, and multidisciplinary support.

In addition to medication, many patients benefit from physiotherapy (to maintain mobility, balance, and prevent falls), occupational therapy (to support daily activities and home modifications), and speech and language therapy (to address voice and swallowing difficulties).

Parkinson's UK provides extensive support resources, including a helpline, local support groups, and online information.

Exercise has strong evidence for improving motor symptoms, balance, and quality of life in Parkinson's disease.

NICE NG71 recommends regular physical activity tailored to the individual's abilities and preferences. Activities such as walking, dancing, tai chi, cycling, and swimming are all beneficial.

When to seek urgent medical advice

Contact your GP, Parkinson's nurse, or NHS 111 if your symptoms are worsening despite treatment, if you develop new or troublesome side effects, or if you notice behavioural changes that may indicate impulse control disorders.

Seek emergency care by calling 999 or attending A&E if you experience sudden confusion, high fever with severe muscle rigidity, unexplained collapse, or if you are unable to take your Parkinson's medication due to vomiting or inability to swallow.

Missed or delayed doses of dopaminergic medication can rapidly worsen Parkinson's symptoms and should be treated as urgent in hospital settings.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Mirapexin 0.18 mg tablets, Summary of Product Characteristics (EMC)
• Pramipexole, British National Formulary (BNF)
• NICE NG71: Parkinson's disease in adults
• NICE CKS: Restless legs syndrome
• Parkinson's disease, NHS
• Restless legs syndrome, NHS
• MHRA Yellow Card Scheme